Perkovic et al. — CREDENCE¶

One-paragraph summary¶

Participants with T2D and albuminuric CKD received canagliflozin or placebo on renin–angiotensin-system blockade. The primary kidney/cardiovascular composite was reduced by 30% (HR 0.70), establishing a dedicated kidney-failure prevention indication (PMID 30990260; NCT02065791 verified live).

Key findings¶

Benefit extended beyond glycaemic efficacy.
Kidney and heart-failure endpoints moved to the centre of T2D care.

Limitations¶

Albuminuric diabetic CKD population; generalisation required later broader trials.
Composite outcome components differ in clinical severity.

Why it matters¶

It converted secondary renal signals into definitive kidney-outcome evidence.

Cited by wiki pages¶

Biomarkers
Clinical trials landscape
Complications
Glycaemic management and legacy trials
Guidelines
Incretin therapies
Overview
Patient experience and advocacy
Red flags and safety
SGLT2 inhibitors
Youth-onset T2D